Mar 19 2009
Following development over the last three years, the NanoVentures Australia Board agreed in February to register the company Quintain NanoSystems, as its venture for conducting the development of imaging and diagnostic tools based on nanoparticles.
Quintain has a portfolio of contrast agent technologies developed with the University of Melbourne, the Baker Heart Research Institute, and RMIT University. Led by Dr Jeanette Pritchard, the Qunitain team has had discussions with potential development partners and investors, and will be presenting to potential stakeholders through April and May of 2009.
Quintain NanoSystems (Quintain NS) is the vehicle established in 2007 from the bionanotechnology activities of Nanotechnology Victoria Ltd. It’s focus is towards development and commercialisation of diagnostic reagents and devices for human and animal health industries.
NanoVentures Australia's initial task is to commercialise the technologies developed under Nanotechnology Victoria Ltd's NanoVic's project agreements over the last six years. It will seek to raise funds to commercialise these technologies, and is able to enter commercial arrangements which were not feasible under NanoVic's corporate structure.